Metagenomi Therapeutics, Inc. (MGX)
Nasdaq: MGX · CIK 0001785279 · United States
Every official Metagenomi Therapeutics, Inc. filing in one place: annual reports, quarterly results, current reports,
proxy statements, shareholding and announcements, straight from the regulator. Free to search.
Open MGX filings
Metagenomi Therapeutics, Inc. documents
- Metagenomi Therapeutics, Inc. 10-K 2026MGX 10-K 2026: annual report for fiscal 2026
- Metagenomi Therapeutics, Inc. 10-K 2025MGX 10-K 2025: annual report for fiscal 2025
- Metagenomi Therapeutics, Inc. 10-K 2024MGX 10-K 2024: annual report for fiscal 2024
- Metagenomi Therapeutics, Inc. 10-K 2023MGX 10-K 2023: annual report for fiscal 2023
- Metagenomi Therapeutics, Inc. 10-K 2022MGX 10-K 2022: annual report for fiscal 2022
- Metagenomi Therapeutics, Inc. 10-Q 2026MGX 10-Q 2026: quarterly report for fiscal 2026
- Metagenomi Therapeutics, Inc. 10-Q 2025MGX 10-Q 2025: quarterly report for fiscal 2025
- Metagenomi Therapeutics, Inc. 10-Q 2024MGX 10-Q 2024: quarterly report for fiscal 2024
- Metagenomi Therapeutics, Inc. 10-Q 2023MGX 10-Q 2023: quarterly report for fiscal 2023
- Metagenomi Therapeutics, Inc. 10-Q 2022MGX 10-Q 2022: quarterly report for fiscal 2022
- Metagenomi Therapeutics, Inc. 8-K 2026MGX 8-K 2026: current report for fiscal 2026
- Metagenomi Therapeutics, Inc. 8-K 2025MGX 8-K 2025: current report for fiscal 2025
- Metagenomi Therapeutics, Inc. 8-K 2024MGX 8-K 2024: current report for fiscal 2024
- Metagenomi Therapeutics, Inc. 8-K 2023MGX 8-K 2023: current report for fiscal 2023
- Metagenomi Therapeutics, Inc. 8-K 2022MGX 8-K 2022: current report for fiscal 2022
- Metagenomi Therapeutics, Inc. DEF 14A 2026MGX DEF 14A 2026: proxy statement for fiscal 2026
- Metagenomi Therapeutics, Inc. DEF 14A 2025MGX DEF 14A 2025: proxy statement for fiscal 2025
- Metagenomi Therapeutics, Inc. DEF 14A 2024MGX DEF 14A 2024: proxy statement for fiscal 2024
- Metagenomi Therapeutics, Inc. DEF 14A 2023MGX DEF 14A 2023: proxy statement for fiscal 2023
- Metagenomi Therapeutics, Inc. DEF 14A 2022MGX DEF 14A 2022: proxy statement for fiscal 2022
- Metagenomi Therapeutics, Inc. Form 4 2026MGX Form 4 2026: insider trading filing for fiscal 2026
- Metagenomi Therapeutics, Inc. Form 4 2025MGX Form 4 2025: insider trading filing for fiscal 2025
- Metagenomi Therapeutics, Inc. Form 4 2024MGX Form 4 2024: insider trading filing for fiscal 2024
- Metagenomi Therapeutics, Inc. Form 4 2023MGX Form 4 2023: insider trading filing for fiscal 2023
- Metagenomi Therapeutics, Inc. Form 4 2022MGX Form 4 2022: insider trading filing for fiscal 2022
- Metagenomi Therapeutics, Inc. S-1 2026MGX S-1 2026: registration statement for fiscal 2026
- Metagenomi Therapeutics, Inc. S-1 2025MGX S-1 2025: registration statement for fiscal 2025
- Metagenomi Therapeutics, Inc. S-1 2024MGX S-1 2024: registration statement for fiscal 2024
- Metagenomi Therapeutics, Inc. S-1 2023MGX S-1 2023: registration statement for fiscal 2023
- Metagenomi Therapeutics, Inc. S-1 2022MGX S-1 2022: registration statement for fiscal 2022
- Metagenomi Therapeutics, Inc. 13F 2026MGX 13F 2026: institutional holdings for fiscal 2026
- Metagenomi Therapeutics, Inc. 13F 2025MGX 13F 2025: institutional holdings for fiscal 2025
- Metagenomi Therapeutics, Inc. 13F 2024MGX 13F 2024: institutional holdings for fiscal 2024
- Metagenomi Therapeutics, Inc. 13F 2023MGX 13F 2023: institutional holdings for fiscal 2023
- Metagenomi Therapeutics, Inc. 13F 2022MGX 13F 2022: institutional holdings for fiscal 2022
More companies